Journal Article

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions

Richter-Ehrenstein, Christiane, Denkert, Carsten, Dietel, Manfred, Schoenegg, Winfried, Schmidt, Marcus, Keil, Elke, Sinn, Bruno Valentin, Budczies, Jan, Lehmann, Annika, Jöhrens, Korinna, Lippek, Frank, Pahl, Stefan, Müller, Berit Maria, Prinzler, Judith, Stadie, Sylvia, Winzer, Klaus-Jürgen, Eucker, Jan, Reles, Angela, Bangemann, Nikola

2013

نظرة عامة

The validated EndoPredict assay is a novel tool to predict the risk of metastases of patients with estrogen receptor positive, HER2 negative breast cancer treated with endocrine therapy alone. It has been designed to integrate genomic and clinical information and includes clinico-pathological factors such as tumor size and nodal status. The test is feasible in a decentral setting in molecular pathology laboratories. In this project, we investigated the performance of this test in clinical practice, and performed a retrospective evaluation of its impact on treatment decisions in breast cancer. During one year, EndoPredict assays from 167 patients could be successfully performed. For retrospective evaluation of treatment decisions, a questionnaire was sent to the clinical partner. Regarding the molecular EP class, samples from 56 patients (33.5%) had a low-risk, whereas 111 patients (66.5%) showed a high-risk gene profile. After integration of the clinicopathological factors the combined clinical and molecular score (EPclin) resulted in a low-risk group of 77 patients (46.4%), while 89 (53.6%) had a high risk EPclin score. The EPclin-based estimated median 10-year-risk for metastases with endocrine therapy alone was 11% for the whole cohort. The median handling time averaged three days (range: 0 to 11 days), 59.3% of the tests could be performed in three or less than three days. Comparison of pre- and post-test therapy decisions showed a change of therapy in 37.7% of patients. 16 patients (12.3%) had a change to an additional chemotherapy while 25.4% of patients (n = 33) changed to an endocrine therapy alone. In 73 patients (56.2%) no change of therapy resulted. In 6.1% of patients (n = 8), the patients did not agree to the recommendation of the tumor board. Our results show that the EndoPredict assay could be routinely performed in decentral molecular pathology laboratories and the results markedly change treatment decisions.

• الناشر: Public Library of Science,Public Library of Science (PLoS)
• موضوع: Adult / Aged / Antineoplastic Agents, Hormonal - therapeutic use / Assaying / Automation / Breast cancer / Breast Neoplasms - diagnosis / Breast Neoplasms - drug therapy / Breast Neoplasms - metabolism / Cancer / Cancer therapies / Chemotherapy / Clinical Decision-Making / Clinical medicine / Decision making / Decisions / Endocrine therapy / ErbB-2 protein / Estrogens / Evaluation / Female / Gene amplification / Gene expression / Gene Expression Profiling - instrumentation / Gynecology / Humans / Information processing / Laboratories / Medical diagnosis / Medical prognosis / Medicine / Metastases / Middle Aged / Pathology / Patients / Receptors, Estrogen - metabolism / Retrospective Studies / Risk / Risk Assessment / Risk groups / Studies / Surveys and Questionnaires